Health Care & Life Sciences » Biotechnology | Prescient Therapeutics Ltd.

Prescient Therapeutics Ltd. | Income Statement

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
-
-
0.20
0.60
1.50
Gross Income
-
-
0.20
0.60
1.50
SG&A Expense
1,777.50
2,384.50
2,749.40
3,762.30
3,604.50
EBIT
-
2,384.50
2,749.60
3,763.00
3,606.00
Non Operating Income/Expense
-
-
7.00
28.90
30.40
Interest Expense
-
-
-
-
2.20
Pretax Income
1,769.40
2,344.50
2,745.90
3,625.70
3,513.50
Income Tax
-
211.10
991.80
1,058.00
939.80
Consolidated Net Income
1,769.40
2,133.40
1,754.10
2,567.60
2,573.70
Net Income
1,769.40
2,133.40
1,754.10
2,567.60
2,573.70
Net Income After Extraordinaries
1,769.40
2,133.40
1,754.10
2,567.60
2,573.70
Net Income Available to Common
1,769.40
2,133.40
1,754.10
2,567.60
2,573.70
EPS (Basic)
1.16
0.04
0.02
0.01
0.01
Basic Shares Outstanding
1,527.20
51,114.30
82,176.70
209,957.80
211,369.80
EPS (Diluted)
1.16
0.04
0.02
0.01
0.01
Diluted Shares Outstanding
1,527.20
51,114.30
82,176.70
209,957.80
211,369.80
EBITDA
-
-
2,749.40
3,762.30
3,604.50
Non-Operating Interest Income
8.10
40.00
10.70
166.20
125.20

About Prescient Therapeutics

View Profile
Address
100 Albert Road
South Melbourne Victoria (VIC) 3205
Australia
Employees -
Website http://www.prescienttherapeutics.com
Updated 07/08/2019
Prescient Therapeutics Ltd. is a biopharmaceutical company, which engages in the discovery and development of novel immunotherapeutic products for the treatment of chronic infectious diseases and cancer. It develops immune therapeutics based upon its Co-X-Gene and fowlpox virus delivery technologies. The company was founded May 22, 1986 and is headquartered in Perth, Australia.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.